About Us


Shukun Technology is a world leading intelligent healthcare technology platform. With the China-originated global advanced technology, Shukun is dedicated to provide intelligent products and innovation solutions to the healthcare industry.

From the in-house developed leading healthcare smart brain —“ Digital Body” technology platform,Shukun has built the most comprehensive “DigitalDoc” product portfolio, which addresses most of the critical therapeutic areas and serves some of the world’s most prevalent and lethal diseases. The “DigitalDoc” product portfolio has already covered full patient journey from disease screening, to diagnosis and treatment planning processes and has been applied in smart imaging, smart surgery and smart health management fields.

As of today, Shukun is the only company who has obtained NMPA Class III certificates and CE MDR markings in Heart, Brain and Chest therapeutic areas worldwide. 

Shukun has the broadest hospital coverage among AI medical imaging solution providers as well. As of today, the “DigitalDoc” products have been adopted and installed in nearly 3,000 healthcare institutions, including approximately 90% of the Top 100 Hospitals and 60% of all Class III Grade A hospitals in China.

Looking forward, Shukun will further enhance the collaboration with top hospitals,industry experts and research institutions, continue to expand AI and other advance technologies’ application in healthcare area, and empower the digitalization and smartification of the healthcare industry worldwide and ultimately, bring accessible intelligence healthcare services to all human beings.

  • Mission

    To empower a new era of smart healthcare by creating an AI-powered Digital Doctor which assists human doctors to deliver much more efficient, accurate, consistent and accessible patient care.

  • Vision

    Provide accessible smart healthcare services to all human beings.

SHUKUN Milestones
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Select year
  • Year2024
    • Released Digital Human 3.0, further advancing the "AI + Healthcare" open technology ecosystem

    • Signed a cooperation agreement with the Wenzhou Health and Wellness Commission to jointly promote high-quality development of the regional healthcare industry

    • Shukun Technology's founder & CEO was selected as one of the 2024 Ernst & Young Asia-Pacific Successful Women Entrepreneurs

    • Won the first prize at the Beijing Artificial Intelligence Industry Large Model Innovation Application Competition

    • Published significant research results on CT-FFR with multiple hospitals in the top journal "Science Bulletin"

    • Included in the 2024 Global Unicorn List

    • Selected as a 2024 Beijing Unicorn Enterprise and signed a major project agreement

  • Year2023
    • Released a comprehensive upgrade of the Digital Human Platform 2.0

    • Introduced a full-link hospital digital intelligence solution for screening, diagnosis, treatment, management, and research

    • Obtained NMPA Class III certificates for eight products, including CT-FFR, Fracture AI, Aneurysm AI, ASPECT Score, Bone Age AI, and Liver MR AI

    • Both Head and Neck CTA and CTP AI received FDA certification

    • Published a high-scoring article in "Radiology"

    • Won the "Typical Scientific and Technological Case Award" from the National Health Commission Capacity Building and Continuing Education Center

    • Received four major awards at the National Digital Health Innovation and Application Competition hosted by the National Health Commission

    • Named a national-level specialized and new "little giant"

    • Awarded the Beijing Science and Technology Progress Award

  • Year2022
    • Obtained NMPA Class III certificates for Head and Neck AI and Lung Nodule AI

    • Digital Doctor products were highly utilized in nearly 3,000 healthcare institutions across the country

    • Signed a strategic partnership with China Unicom (Guangdong) Industrial Internet Co., Ltd

    • Signed a strategic agreement with the government of Songjiang District, Shanghai

    • As the only representative of technology startups and medical AI companies, we were invited to the Boao Forum for Asia Annual Conference 2022

    • Selected by the Ministry of Industry and Information Technology and the National Medical Products Administration for two national innovation projects

    • Named the only medical AI company on the 2022 Beijing Private Enterprises "Top 100 in Scientific and Technological Innovation" list

    • Included in Fortune's 2022 list of China's Most Socially Influential Startups

    • Shukun Technology's founder and CEO, Ma Chun'e, was selected as one of Forbes China's "20 Potential Women in Chinese Business 2022" (selected for three consecutive years)

  • Year2021
    • Globally launched Digital Abdomen AI and Digital Human

    • Obtained NMPA Class III certificate for Pneumonia AI

    • Coronary AI, Pneumonia AI, Head and Neck AI, and Lung Nodule AI received EU MDR CE certificates

    • Digital Doctor products were highly utilized in over 1,000 public hospitals across the country

    • Completed D round of funding, led by Goldman Sachs Asset Management and Primavera Capital, with joint investment from Sequoia Capital China and General Atlantic

    • Established a strategic partnership with Meinian Onehealth, a leading preventive healthcare company

    • Included in the CBInsights Global Digital Health 150 list

  • Year2020
    • Released a cardio-pulmonary joint screening product, introducing Digital Chest AI

    • Obtained the world's first NMPA Class III certificate for cardiovascular AI

    • Completed B round of funding, led by BOC International, with joint investment from Qiming Venture Partners, CCB International, and Langmafeng Venture Capital. Longtime shareholders such as Creation Ventures and Huagai Capital also participated

    • Completed C round of funding, led by Sequoia Capital China, with follow-on investment from China Re Group and CICC Pucheng. Longtime shareholders such as Huagai Capital and Vision Capital continued to follow on

    • Published a high-scoring article in a Nature subsidiary journal

    • Featured in a full-page report in People's Daily, highlighting the implementation of medical AI at Beijing Anzhen Hospital using Shukun AI

    • Represented as a tech-based epidemic prevention enterprise at a Beijing press conference

    • Shukun Technology's founder and CEO, Ma Chun'e, was selected by Fortune magazine as one of the "40 Business Elites Under 40 Globally"

  • Year2019
    • Globally launched Digital Brain AI

    • Completed A+ round of funding, led by Creation Ventures, with follow-on investment from existing shareholders Vision Capital and Huagai Capital

    • Obtained the world's first gold standard multi-center validation, registered with the WHO.

    • Established strategic agreements with Philips and GE

  • Year2018
    • Globally launched Digital Heart AI

    • Completed A round of funding, jointly led by Vision Capital and Huagai Capital, with follow-on investment from Yuanyi Capital

    • Awarded "2018 China Rising Star" by Deloitte, known as the "Oscars of China's Technology Industry"

  • Year2017
    • Established Shukun Technology

    • Began research and development on cardiovascular AI

    • Received angel investment from Yuanyi Capital

 Contact Us 
在数坤一展所长 共护人类健康
Contact Us
Request a demo
lnterested in our product?
I have read and fully agree to the terms of Consent to the Personal Information Collection and Instructions

Personal Information Collection and Instructions

Shukun(Beijing) Technology Co.,Ltd. (herein after referred to as “Our Company”) attaches great importance to your privacy and highly appreciates your trust. Our Company would like to inform you the purpose for collecting information, contents of information collected, method that information will be processed, and that you may revoke your authorization at any time.

1. Purpose
(1) To identify the specific person or entity submitting the trial application.
(2) To respond to or provide services for the aforesaid applicant or entity.

2. Collected information
Our Company will collect the following information:
(1) Required information includes: Name, E-mail Address, Country, Phone Number, Job Title, Facility/Company Name, Product Interest, How can we help you?

3. How long will your information be kept?
From the time you authorize Our Company to collect information to the time you revoke the authorization.

4. Refusal to provide information
You are authorized to refuse to provide your information.
If you refuse to provide any of the required information, our Company will not be able to contact you accurately and provide you with our services. Please contact us by other means.
If you refuse to provide any of the optional information, our Company may have difficulties in actively providing you with our services. You may contact us at any time.